Apister Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 17.90 Cr
as on 08-12-2024
- Revenue -8.14%
(FY 2022)
- Profit 37.17%
(FY 2022)
- Ebitda 22.93%
(FY 2022)
- Net Worth 83.47%
(FY 2022)
- Total Assets 19.09%
(FY 2022)
About Apister Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹17.90 Cr.
Hasmukhbhai Patel, Jayeshkumar Patel, and Prashantkumar Patel serve as directors at the Company.
- CIN/LLPIN
U24304GJ2017PTC097161
- Company No.
097161
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Apister Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hasmukhbhai Patel  | Director | 21-Jan-2019 | Current |
| Jayeshkumar Patel | Director | 08-May-2019 | Current |
| Prashantkumar Patel | Director | 08-May-2019 | Current |
Financial Performance of Apister Lifesciences.
Apister Lifesciences Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.14% decrease. The company also saw a substantial improvement in profitability, with a 37.17% increase in profit. The company's net worth Soared by an impressive increase of 83.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apister Lifesciences?
In 2022, Apister Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Polycarb Advance Science Private LimitedActive 4 years 2 monthsPrashantkumar Patel is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Jul 2020 | ₹8.00 Cr | Open |
Others Creation Date: 24 Apr 2020 | ₹2.50 M | Open |
Others Creation Date: 11 Aug 2017 | ₹9.65 Cr | Open |
How Many Employees Work at Apister Lifesciences?
Apister Lifesciences has a workforce of 54 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apister Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apister Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
